论文部分内容阅读
目的探讨替罗非班联合阿托伐他汀对急性心肌梗死(AMI)患者血清基质金属蛋白酶-9(MMP-9)、超敏C反应蛋白(hs-CRP)、N末端脑钠肽前体(NT-proBNP)变化及预后的影响。方法选取2014年7月至2016年9月沈丘县中医院106例AMI患者,根据治疗方案分组,各53例。对照组在常规治疗基础上给予替罗非班治疗,观察组给予替罗非班+阿托伐他汀治疗。对比两组治疗前后血清MMP-9、hs-CRP、NT-proBNP水平,并随访3个月,统计两组不良心脏事件发生率。结果治疗前两组MMP-9、hs-CRP、NT-proBNP水平差异无统计学意义(P>0.05),治疗后,观察组MMP-9、hs-CRP、NT-proBNP水平均低于对照组,差异有统计学意义(P<0.05);观察组不良心脏事件发生率为3.77%(2/53),低于对照组的15.09%(8/53),差异有统计学意义(P<0.05)。结论给予AMI替罗非班联合阿托伐他汀治疗,可有效降低患者血清MMP-9、hs-CRP、NT-proBNP水平,进而有利于改善预后。
Objective To investigate the effects of tirofiban combined with atorvastatin on serum matrix metalloproteinase-9, hs-CRP, N-terminal pro brain natriuretic peptide (AMN) in patients with acute myocardial infarction NT-proBNP) changes and prognosis. Methods From July 2014 to September 2016, 106 patients with AMI in Shenqiu Chinese Medicine Hospital were selected and divided into three groups according to the treatment plan. The control group was given tirofiban on the basis of routine treatment, while the observation group was given tirofiban + atorvastatin. The levels of serum MMP-9, hs-CRP and NT-proBNP were compared between the two groups before and after treatment. The incidences of adverse cardiac events were calculated after 3 months of follow-up. Results There was no significant difference in the levels of MMP-9, hs-CRP and NT-proBNP between the two groups before treatment (P> 0.05). After treatment, the levels of MMP-9, hs-CRP and NT-proBNP in the observation group were lower than those in the control group , The difference was statistically significant (P <0.05). The incidence of adverse cardiac events in the observation group was 3.77% (2/53), which was lower than that in the control group (15.09%, 8/53) ). Conclusions The administration of tirofiban AMI combined with atorvastatin can effectively reduce the levels of serum MMP-9, hs-CRP and NT-proBNP in patients and further improve the prognosis.